KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Discontinued OperationsCash from Discontinued OperationsCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Gains from Sales and Divestitures (2019 - 2025)

TherapeuticsMD filings provide 8 years of Gains from Sales and Divestitures readings, the most recent being $5000.0 for Q4 2025.

  • On a quarterly basis, Gains from Sales and Divestitures fell 28.57% to $5000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $5000.0, a 28.57% decrease, with the full-year FY2025 number at $5000.0, down 28.57% from a year prior.
  • Gains from Sales and Divestitures hit $5000.0 in Q4 2025 for TherapeuticsMD, roughly flat from $5000.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $2.0 million in Q3 2021 to a low of $2.0 in Q1 2024.
  • Median Gains from Sales and Divestitures over the past 5 years was $7000.0 (2023), compared with a mean of $206883.4.
  • Biggest five-year swings in Gains from Sales and Divestitures: crashed 99.61% in 2022 and later surged 99900.0% in 2025.
  • TherapeuticsMD's Gains from Sales and Divestitures stood at $34000.0 in 2021, then crashed by 99.61% to $133.0 in 2022, then soared by 5163.16% to $7000.0 in 2023, then changed by 0.0% to $7000.0 in 2024, then fell by 28.57% to $5000.0 in 2025.
  • The last three reported values for Gains from Sales and Divestitures were $5000.0 (Q4 2025), $5000.0 (Q3 2025), and $5000.0 (Q2 2025) per Business Quant data.